May 28, 2025, 12:08
The Ideal Healthcare Pathway by the GUIDE.MRD project is published as an ASCO 2025 Abstract – Lung Cancer Europe
Lung Cancer Europe shared a post on LinkedIn:
“ctDNA and MRD: a new model for cancer follow-up care.
The Ideal Healthcare Pathway, developed by the GUIDE.MRD project, is now live and has been published as an abstract for ASCO 2025.
It sets out a new approach to follow-up care after cancer treatment, using circulating tumour DNA (ctDNA) testing to detect Minimal Residual Disease (MRD).
This can help find recurrence earlier, reduce unnecessary treatment, and support more personalised care.
As a consortium partner in GUIDE.MRD Lung Cancer Europe has helped bring the lung cancer perspective into this work, thanks to the engagement of patients in co-creation and multi-stakeholder dialogues.
You can explore the abstract.
With thanks to Klaus Pantel for coordinating this project.”
Abstract Title: Creation of the ideal health care pathway for integrating ctDNA testing into clinical practice through multi-stakeholder engagement.
Authors: Lidewij Vat, Brian Goodman, Eleonora Barile, Estevan Kiernan, Bianca Cucoș, Ana Martins, Mohan Bolisetty, Cathy Elks, Ryan Demers, Muriel De Vos, Riccardo Bertini, Trixia Camacho, Daniel J. Smit, Luigi Ravagnan, Klaus Pantel
Read Full Abstract on ASCO.
More posts featuring ASCO25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 14:15
May 29, 2025, 13:35
May 29, 2025, 13:11
May 29, 2025, 12:46